Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
1.
BMJ ; 378: o1772, 2022 07 15.
Article in English | MEDLINE | ID: covidwho-1950090
2.
New Sci ; 255(3393): 16, 2022 Jul 02.
Article in English | MEDLINE | ID: covidwho-1915189
3.
BMJ ; 377: o1555, 2022 06 28.
Article in English | MEDLINE | ID: covidwho-1909714
5.
JCI Insight ; 7(13)2022 07 08.
Article in English | MEDLINE | ID: covidwho-1861743

ABSTRACT

The role of immune responses to previously seen endemic coronavirus epitopes in severe acute respiratory coronavirus 2 (SARS-CoV-2) infection and disease progression has not yet been determined. Here, we show that a key characteristic of fatal outcomes with coronavirus disease 2019 (COVID-19) is that the immune response to the SARS-CoV-2 spike protein is enriched for antibodies directed against epitopes shared with endemic beta-coronaviruses and has a lower proportion of antibodies targeting the more protective variable regions of the spike. The magnitude of antibody responses to the SARS-CoV-2 full-length spike protein, its domains and subunits, and the SARS-CoV-2 nucleocapsid also correlated strongly with responses to the endemic beta-coronavirus spike proteins in individuals admitted to an intensive care unit (ICU) with fatal COVID-19 outcomes, but not in individuals with nonfatal outcomes. This correlation was found to be due to the antibody response directed at the S2 subunit of the SARS-CoV-2 spike protein, which has the highest degree of conservation between the beta-coronavirus spike proteins. Intriguingly, antibody responses to the less cross-reactive SARS-CoV-2 nucleocapsid were not significantly different in individuals who were admitted to an ICU with fatal and nonfatal outcomes, suggesting an antibody profile in individuals with fatal outcomes consistent with an "original antigenic sin" type response.


Subject(s)
COVID-19 , Spike Glycoprotein, Coronavirus , Antibodies, Viral , Antibody Formation , Epitopes , Humans , SARS-CoV-2
7.
New Sci ; 253(3374): 12, 2022 Feb 19.
Article in English | MEDLINE | ID: covidwho-1688980
8.
BMJ ; 376: o298, 2022 Feb 04.
Article in English | MEDLINE | ID: covidwho-1673407
9.
New Sci ; 252(3364): 8, 2021 Dec 11.
Article in English | MEDLINE | ID: covidwho-1559540
10.
BMJ ; 375: n2597, 2021 10 27.
Article in English | MEDLINE | ID: covidwho-1495421
11.
New Sci ; 251(3355): 8-9, 2021 Oct 09.
Article in English | MEDLINE | ID: covidwho-1458823

ABSTRACT

People in the UK are trying to source a parasite drug to use as an unproven treatment for covid-19, reveals Chris Stokel-Walker.

12.
BMJ ; 374: n2165, 2021 Sep 20.
Article in English | MEDLINE | ID: covidwho-1430183
13.
New Sci ; 251(3350): 8, 2021 Sep 04.
Article in English | MEDLINE | ID: covidwho-1382938
14.
BMJ ; 374: n2053, 2021 Aug 24.
Article in English | MEDLINE | ID: covidwho-1371888
15.
BMJ ; 373: n1645, 2021 06 29.
Article in English | MEDLINE | ID: covidwho-1288375
16.
BMJ ; 373: n1299, 2021 May 26.
Article in English | MEDLINE | ID: covidwho-1247344
17.
BMJ ; 372: n681, 2021 Mar 23.
Article in English | MEDLINE | ID: covidwho-1148136
18.
BMJ ; 372: n327, 2021 02 08.
Article in English | MEDLINE | ID: covidwho-1072742
19.
BMJ ; 372: n99, 2021 01 19.
Article in English | MEDLINE | ID: covidwho-1038414
20.
BMJ ; 371: m3603, 2020 10 06.
Article in English | MEDLINE | ID: covidwho-1007308
SELECTION OF CITATIONS
SEARCH DETAIL